Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.76 |
| ▸ | HTR2A | P28223 | 3/20 | 0.76 |
| ▸ | HTR1A | P08908 | 2/20 | 0.76 |
| ▸ | HTR2C | P28335 | 2/20 | 0.76 |
| ▸ | MLNR | O43193 | 1/20 | 0.76 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.76 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.76 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.76 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.76 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.76 |
| ▸ | CNR1 | P21554 | 1/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.76 |
| ▸ | NPY1R | P25929 | 1/20 | 0.76 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2257177 | 1.00 | DRD2 (0.76) | DRD2HTR2AHTR1AHTR2CMLNR | |
| SCHEMBL12291636 | 1.00 | DRD2 (0.76) | DRD2HTR2AHTR1AHTR2CMLNR | |
| SCHEMBL29386388 | 1.00 | DRD2 (0.76) | DRD2HTR2AHTR1AHTR2CMLNR | |
| SCHEMBL2256345 | 1.00 | DRD2 (0.76) | DRD2HTR2AHTR1AHTR2CMLNR | |
| SCHEMBL2256343 | 1.00 | DRD2 (0.76) | DRD2HTR2AHTR1AHTR2CMLNR | |
| SCHEMBL29389510 | 1.00 | DRD2 (0.76) | DRD2HTR2AHTR1AHTR2CMLNR | |
| SCHEMBL19988042 | 1.00 | DRD2 (0.76) | DRD2HTR2AHTR1AHTR2CMLNR | |
| SCHEMBL2282055 | 1.00 | DRD2 (0.76) | DRD2HTR2AHTR1AHTR2CMLNR | |
| SCHEMBL2282050 | 1.00 | DRD2 (0.76) | DRD2HTR2AHTR1AHTR2CMLNR | |
| SCHEMBL2257084 | 1.00 | DRD2 (0.76) | DRD2HTR2AHTR1AHTR2CMLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3974419-A2 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2022-03-30 | — | — | EP | disclosed |
| US-20220056003-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2022-02-24 | — | — | US | disclosed |
| CN-113563295-A | Synthesis method of nebivolol and intermediate compound thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO LTD | 2021-10-29 | — | — | CN | disclosed |
| EP-3299364-B1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| US-11142512-B2 | Nebivolol synthesis method and intermediate compound thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| CN-107531662-B | Synthesis method of nebivolol and intermediate compound thereof | 浙江奥翔药业股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20200102282-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2020-04-02 | — | — | US | disclosed |
| US-20180141926-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-05-24 | — | — | US | disclosed |
| US-20180141926-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-05-24 | — | — | US | disclosed |
| EP-3299364-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2018-03-28 | — | — | EP | disclosed |
| EP-2102196-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZaCh System S.p.A. (IT) | 2009-09-23 | — | — | EP | disclosed |
| US-7560575-B2 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2009-07-14 | — | — | US | disclosed |
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (CH) | 2009-02-19 | — | — | US | disclosed |
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (CH) | 2009-02-19 | — | — | US | disclosed |
| WO-2008064826-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008064827-A2 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008010022-A2 | A PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1803715-A1 | A process for preparation of racemic nebivolol | Cimex Pharma AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| US-20070149612-A1 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2007-06-28 | — | — | US | disclosed |
| US-20070014733-A1 | Hydroxylated nebivolol metabolites | DEY PHARMA, L.P. (F/K/A DEY L.P.) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | ADRB1, ADRB2, ADRA2B | DRD2 60/4885HTR2A 131/4885HTR1A 101/4885 |
| US-20200102282-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | CYP4A11, CYP11B2, ADRB1 | DRD2 205/4885HTR2A 1349/4885HTR1A 1318/4885 |
| US-11142512-B2 | Nebivolol synthesis method and intermediate compound thereof | CYP4A11, CYP11B2, ADRB1 | DRD2 205/4885HTR2A 1349/4885HTR1A 1318/4885 |
| US-20220056003-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | CYP4A11, CYP11B2, CYP11B1 | DRD2 222/4885HTR2A 1351/4885HTR1A 1267/4885 |
| US-20070149612-A1 | Process for preparation of racemic Nebivolol | ADRB1, ADRB2, ADRA2B | DRD2 60/4885HTR2A 131/4885HTR1A 101/4885 |
| US-20180141926-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | CYP4A11, CYP11B2, ADRB1 | DRD2 205/4885HTR2A 1349/4885HTR1A 1318/4885 |
| US-20070014733-A1 | Hydroxylated nebivolol metabolites | EDNRB, EDNRA, ADRB1 | DRD2 902/4885HTR2A 245/4885HTR1A 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.